Clinical Trial

A Study of TIL in Advanced Solid Tumors (DFGD)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-28; most recent amendment 2025-12-08.
Trial Details
NCT Number NCT06488950
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Eastern Hepatobiliary Surgery Hospital
Conditions Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
Enrollment 30 participants
Start Date 2023-04-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-16